On the basis of results of the most recent CVOTs (DAPA-HF, DAPA-CKD, EMPEROR-R), the FDA has approved dapagliflozin (2020) and empagliflozin (2021) to reduce risk for CV death and HF hospitalization in adults with HF and reduced ejection fraction regardless of whether they have diabetes [24, 25]
Like BPC-157, it has a substantial following in athletic and biohacking communities
Many users find Semaglutide safe and effective
Unlike medications that produce rapid initial results, natural approaches require patience and consistency
Kidney Problems: Although uncommon, some users may experience kidney-related side effects
If your health provider determines that a dosage of 1.7 mg is effective for you, they may have you stick to that dosage moving forward